Influence of SPINK1 Gene Polymorphism on Efficacy of Ulinastatin in Treatment of Acute Pancreatitis / 胃肠病学

ABSTRACT

Background: Ulinastatin is an important drug for the treatment of acute pancreatitis (AP). However, there are some differences in the efficacy of ulinastatin among different patients. Aims: To explore influence of SPINK1 gene polymorphism on the efficacy of ulinastatin in treatment of AP. Methods: A total of 572 patients with AP from January 2005 to December 2015 at Baoji Hospital of Traditional Chinese Medicine were enrolled. Ulinastatin 100 000 U was given intravenously. Mutation of SPINK1 gene was detected by PCR. The levels of TNF-α, IL-2, IL-8, IL-10 and blood, urine amylase were determined by ELISA. The efficacy of ulinastatin was evaluated. Results: Rate of c.101A>G mutation in AP patients was significantly higher than that in the control group (PA mutation resulted in a significant decrease of SPINK1 mRNA expression (PC and c.200G>A mutations than in wild type (PA mutation were significantly decreased than those in wild type (PA mutation (PC and c.200G>A mutations was significantly lower than that in wild type (PG mutation in patients with AP is higher than that in general population. Mutations of c. 36G>C and c.200G>A could influence the efficacy of ulinastatin for the treatment of AP.